• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction

    10/24/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email

    Appalled that STAAR's Board Reneged on Its Promise to Let Shareholders Decide the Fate of the Proposed Transaction in a Timely Manner

    Urges STAAR to Give Up on Misbegotten Transaction and Refocus on Running the Business

    Intends to Seek Removal of STAAR Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher from the Board at a Special Meeting

    Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which owns 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today issued the following statement regarding the agreement between STAAR and Alcon Inc. ("Alcon") (NYSE:ALC) to postpone a shareholder vote on the proposed sale of the Company.

    Neal C. Bradsher, Broadwood Founder and President, said:

    "The decision to postpone a shareholder vote on the sale of STAAR to Alcon is the latest in a long string of bad decisions by this Board, which ran a deeply flawed sale process at the wrong time and agreed to an inadequate price. For these reasons, all three major proxy advisory firms oppose the proposed transaction.

    A little more than two weeks ago, the Board said: ‘[T]he ultimate decision rests in the hands of all STAAR stockholders, which is exactly where it should be.' But now, faced with overwhelming and public shareholder opposition to the deal, the Board, with full visibility into the vote tally, has stripped shareholders of their right to a timely final vote.

    Shareholders can reasonably assume that no such postponement would have occurred if the vote tally had been favorable to the deal.

    It is time for STAAR to move past this ill-conceived transaction and get back to the important work of operating and building the business. The adjournment of the vote prolongs the uncertainty surrounding the Company and risks further disrupting STAAR's momentum.

    This Board clearly does not have a mandate to make any changes to the proposed transaction or further delay the termination of the agreement. We call upon the Board to let shareholders vote.

    Moreover, we continue to believe that shareholder confidence in the Board can be restored only by removing directors. To that end, we intend to seek the removal of Board Chair Elizabeth Yeu, who was a consultant to Alcon until very recently; CEO Stephen Farrell, who stands to make $24 million from the sale of STAAR after just five months in his role; and the Board's Compensation Committee Chair, Arthur Butcher, who approved egregious exit compensation packages for executives in conjunction with the transaction. We intend to proceed with our efforts to call a Special Meeting to remove these directors."

    Broadwood encourages its fellow shareholders to review its materials at www.LetSTAARShine.com, and to vote on its GREEN Proxy Card "AGAINST" the proposed transaction.

    About Broadwood

    Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal C. Bradsher is the President of Broadwood Capital.

    Certain Information Concerning the Participants

    Special Meeting of Shareholders Scheduled for October 23, 2025

    Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the shareholders of STAAR in connection with the special meeting of shareholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the "Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company's shareholders for the Special Meeting. SHAREHOLDERS OF STAAR ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of STAAR's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Special Meeting of Shareholders to Remove Members of the Board

    The Participants also intend to file a definitive proxy statement and an accompanying GREEN Proxy Card with the SEC to be used to solicit proxies with respect to removing members of the Board and any other proposals that may come before a future and yet to be called or otherwise scheduled special meeting of shareholders (including any adjournments, postponements, reschedulings or continuations thereof, the "Shareholder Meeting"). The Shareholder Meeting will be separate, distinct and unrelated to the Special Meeting, and the Participants believe that the Shareholder Meeting will have no effect on the outcome of the Special Meeting. The Participants do not believe that there is any lawful reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder vote at the Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise challenge, the Participants' ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on October 22, 2025 and is available here.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251023644800/en/

    Investor Contacts

    John Ferguson / Joseph Mills

    Saratoga Proxy Consulting LLC

    [email protected]

    [email protected]

    (212) 257-1311

    (888) 368-0379

    Media Contacts

    Scott Deveau / Jeremy Jacobs

    August Strategic Communications

    [email protected]

    (323) 892-5562

    Get the next $ALC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC
    $STAA

    CompanyDatePrice TargetRatingAnalyst
    Alcon Inc.
    $ALC
    8/21/2025Overweight → Neutral
    Analyst
    Alcon Inc.
    $ALC
    5/20/2025Buy → Hold
    Deutsche Bank
    Alcon Inc.
    $ALC
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    STAAR Surgical Company
    $STAA
    4/21/2025$17.00Equal Weight
    Wells Fargo
    Alcon Inc.
    $ALC
    3/28/2025$107.00 → $110.00Buy
    Needham
    Alcon Inc.
    $ALC
    3/25/2025Neutral → Buy
    BofA Securities
    STAAR Surgical Company
    $STAA
    2/12/2025Buy → Hold
    Jefferies
    STAAR Surgical Company
    $STAA
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    More analyst ratings

    $ALC
    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Amendments to Alcon Merger Agreement

    30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Superior Proposal from a Qualified Bidder Alcon Waives All Matching Rights for Third-Party Proposals Alcon Waives Information Rights During the Go Shop Period Alcon to Engage with STAAR Stockholders to Solicit Support in Favor of the Merger Proposal STAAR Special Meeting of Stockholders Postponed to December 19, 2025 to Provide Time for Third-Party Proposals STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that

    11/7/25 10:10:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jiang Wei converted options into 20,967 shares, increasing direct ownership by 592% to 24,510 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    8/13/25 6:39:57 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:31:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Zhou Lilian Yansheng

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:29:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon downgraded by Analyst

    Analyst downgraded Alcon from Overweight to Neutral

    8/21/25 8:12:09 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Deutsche Bank

    Deutsche Bank downgraded Alcon from Buy to Hold

    5/20/25 8:02:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    BTIG Research reiterated coverage on Alcon with a new price target

    BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

    5/14/25 11:06:26 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    11/12/25 6:18:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form DFAN14A filed by STAAR Surgical Company

    DFAN14A - STAAR SURGICAL CO (0000718937) (Subject)

    11/10/25 5:00:42 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    11/7/25 1:11:25 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/10/25 7:00:22 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/7/25 8:28:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $941,285 worth of shares (53,969 units at $17.44) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/2/25 8:33:34 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Financials

    Live finance-specific insights

    View All

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Third Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025. Third Quarter 2025 Financial Overview Net sales of $94.7 million up 6.9% Y/Y Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the "December China Shipment") Net sales excluding China of $38.9 million up 7.7% Y/Y Gross margin at 82.2% vs. 77.3% year ago due to the timing of the reco

    11/5/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has

    6/25/25 9:28:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Leadership Transition

    Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

    2/26/25 4:45:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care